Lisata Therapeutics Inc
LSTA2.605USD
+0.115+4.62%
Market hours （ET）Quotes delayed by 15 min
22.46MMarket Cap
LossP/E TTM
More Details of Lisata Therapeutics Inc Company
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 also has the potential to modify the tumor microenvironment (TME). It is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors. Its CD34+ is a cell therapy technology was targeting an array of diseases, among them, critical limb ischemia, coronary microvascular dysfunction, and diabetic kidney disease.
Company Info
Ticker SymbolLSTA
Company nameLisata Therapeutics Inc
IPO dateNov 03, 1995
CEODr. David J. Mazzo, Ph.D.
Number of employees26
Security typeOrdinary Share
Fiscal year-endNov 03
Address110 Allen Road
CityBASKING RIDGE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code07920
Phone19082292590
Websitehttps://www.lisata.com/
Ticker SymbolLSTA
IPO dateNov 03, 1995
CEODr. David J. Mazzo, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. David J. Mazzo, Ph.D.
Dr. David J. Mazzo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
264.69K
+3.26%
Dr. Kristen K. Buck, M.D.
Dr. Kristen K. Buck, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
79.79K
--
Dr. Mohammad Azab, M.D.
Dr. Mohammad Azab, M.D.
Independent Director
Independent Director
52.28K
+23.92%
Mr. Steven Mark (Steve) Klosk, J.D.
Mr. Steven Mark (Steve) Klosk, J.D.
Independent Director
Independent Director
49.57K
+8.05%
Dr. Gregory B. Brown, M.D.
Dr. Gregory B. Brown, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
49.41K
+8.07%
Ms. Heidi Henson, CPA
Ms. Heidi Henson, CPA
Independent Director
Independent Director
39.48K
+10.31%
Tariq Imam
Tariq Imam
Senior Vice President, Business Development and Operations and General Counsel
Senior Vice President, Business Development and Operations and General Counsel
24.58K
--
Mr. James Nisco
Mr. James Nisco
Senior Vice President - Finance and Treasury, Chief Accounting Officer
Senior Vice President - Finance and Treasury, Chief Accounting Officer
23.49K
--
Mr. John D. Menditto
Mr. John D. Menditto
Vice President - Investor Relations & Corporate Communications
Vice President - Investor Relations & Corporate Communications
--
--
Ms. Cynthia L. Flowers
Ms. Cynthia L. Flowers
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. David J. Mazzo, Ph.D.
Dr. David J. Mazzo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
264.69K
+3.26%
Dr. Kristen K. Buck, M.D.
Dr. Kristen K. Buck, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
79.79K
--
Dr. Mohammad Azab, M.D.
Dr. Mohammad Azab, M.D.
Independent Director
Independent Director
52.28K
+23.92%
Mr. Steven Mark (Steve) Klosk, J.D.
Mr. Steven Mark (Steve) Klosk, J.D.
Independent Director
Independent Director
49.57K
+8.05%
Dr. Gregory B. Brown, M.D.
Dr. Gregory B. Brown, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
49.41K
+8.07%
Ms. Heidi Henson, CPA
Ms. Heidi Henson, CPA
Independent Director
Independent Director
39.48K
+10.31%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Ruoslahti (Erkki)
12.83%
Mazzo (David J)
3.08%
The Vanguard Group, Inc.
2.96%
BML Capital Management LLC
2.52%
Renaissance Technologies LLC
1.19%
Other
77.42%
Shareholders
Shareholders
Proportion
Ruoslahti (Erkki)
12.83%
Mazzo (David J)
3.08%
The Vanguard Group, Inc.
2.96%
BML Capital Management LLC
2.52%
Renaissance Technologies LLC
1.19%
Other
77.42%
Shareholder Types
Shareholders
Proportion
Individual Investor
20.18%
Investment Advisor/Hedge Fund
4.24%
Investment Advisor
3.51%
Hedge Fund
1.22%
Research Firm
0.14%
Other
70.70%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
48
2.52M
29.30%
-63.24K
2025Q1
50
2.57M
30.49%
+155.41K
2024Q4
48
2.39M
27.90%
-46.00K
2024Q3
48
2.33M
27.50%
-84.74K
2024Q2
59
2.31M
27.35%
-158.27K
2024Q1
60
2.32M
28.57%
+1.21M
2023Q4
63
2.13M
26.53%
+1.00M
2023Q3
72
2.18M
28.45%
+396.20K
2023Q2
72
2.18M
28.62%
+428.28K
2023Q1
74
1.03M
14.30%
-575.31K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Ruoslahti (Erkki)
1.10M
12.83%
-78.14K
-6.62%
Apr 17, 2025
Mazzo (David J)
264.69K
3.08%
+8.35K
+3.26%
Apr 17, 2025
The Vanguard Group, Inc.
254.18K
2.96%
+67.82K
+36.39%
Mar 31, 2025
BML Capital Management LLC
216.85K
2.52%
-67.82K
-23.82%
Mar 31, 2025
Renaissance Technologies LLC
102.72K
1.19%
+1.40K
+1.38%
Mar 31, 2025
Buck (Kristen K)
79.79K
0.93%
--
--
Apr 17, 2025
Geode Capital Management, L.L.C.
60.53K
0.7%
+4.63K
+8.29%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
54.86K
0.64%
-1.16K
-2.06%
Mar 31, 2025
Azab (Mohammad)
52.28K
0.61%
+10.09K
+23.92%
Apr 17, 2025
Klosk (Steven Mark)
49.57K
0.58%
+3.69K
+8.05%
Apr 17, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Sep 14, 2022
Merger
15<1
Sep 14, 2022
Merger
15<1
Sep 14, 2022
Merger
15<1
Sep 14, 2022
Merger
15<1
Date
Type
Ratio
Sep 14, 2022
Merger
15<1
Sep 14, 2022
Merger
15<1
Sep 14, 2022
Merger
15<1
Sep 14, 2022
Merger
15<1
